

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/533,290 Confirmation-No.: 6045
 Applicant : Thor Las HOLTET, et al.
 Filed : April 29, 2005
 Title : TRIMERIC BINDING PROTEINS FOR TRIMERIC CYTOKINES
 TC/Art Unit : To Be Assigned
 Examiner: To Be Assigned

 Docket No. : 66611.000011
 Customer No. : 21967

MAIL STOP AMENDMENT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants submit attached Form PTO-SB/08A (modified) for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

In accordance with 37 C.F.R. § 1.98(a)(2)(ii), copies of cited U.S. patents and/or U.S. patent application publications under 35 U.S.C. 371, are not being provided.

The attached documents were cited by the European Patent Office in the European Search Report dated March 8, 2006 of a corresponding application and relevance as asserted by the Searching Authority is indicated on the enclosed copy of the Search Report.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

BEST AVAILABLE COPY

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references is enclosed with this communication.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.


In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: April 7, 2006

By:


Robert C. Lampe III
Registration No. 51,914

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)
RCL/asc



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/533,290
Filing Date	April 29, 2005
First Named Inventor	Thor Las HOLTET, et al.
Art Unit	To Be Assigned
Examiner Name	To Be Assigned

Sheet	1 of 2	Attorney Docket Number	66611.000011
--------------	---------------	-------------------------------	---------------------

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
1.	US-	5,716,805	02-10-1998	Srinivasan, et al.	
	US-				

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code Number-Kind Code (if known)					YES	NO
2.	WO	2005/047850 A2	05-26-2005	Liang			<input type="checkbox"/>	<input type="checkbox"/>
3.	WO	2004/033486 A2	04-22-2004	West, et al.			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION
			YES NO
4.		International Search Report in PCT/DK03/00735, dated July 26, 2004.	<input type="checkbox"/> <input type="checkbox"/>
5.		Butler, et al., "TNF Receptor Fusion Proteins are Effective Inhibitors of TNF-Mediated Cytotoxicity on Human KYM-1D4 Rhabdomyosarcoma Cells", Cytokine, Vol. 6, No. 6, pg. 616-623, November 1994.	<input type="checkbox"/> <input type="checkbox"/>
6.		Scallion, et al., "Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists", The Journal of Pharmacology and Experimental Therapeutics, Vol. 301, No. 2, pg. 418-426, 2002.	<input type="checkbox"/> <input type="checkbox"/>
7.		Werneburg, et al., "Molecular Characterization of CD40 Signaling Intermediates", The Journal of Biological Chemistry, Vol. 276, No. 46, pg. 43334-43342, November 16, 2001.	<input type="checkbox"/> <input type="checkbox"/>

EXAMINER SIGNATURE	DATE CONSIDERED
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER SIGNATURE		DATE CONSIDERED
Initials Name	Transliteration Title	Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu e number(s), publisher, city and/or country where published
8.	Wuest, et al., "TNF-Selective: A Novel Prodrug generated for Tumor Targeting and Site-Specific Activation of Tumor Necrosis Factor", Oncogene, Vol. 21, pg. 4257-4265, 2002.	
9.	MacEwan, "TNF Ligands and Receptors - A Matter of Life and Death", British Journal of Pharmacology, Vol. 135, pg. 855-875, 2002.	
10.	Peng, et al., "Inhibition of Tumor Necrosis Factor Alpha by an Adenovirus-Encoded Soluble Fusion Protein Extends Expression in the Liver and Lung", Journal of Virology, Vol. 73, No. 6, pg. 5098-5109, June 1999.	
11.	Lane, et al., "Soluble CD40 Ligand Can Replace the Normal T Cell-derived CD40 Ligand Signaling to B Cells in T Cell-dependent Activation", J. Exp. Med., Vol. 177, pg. 1209-1213, April 1993.	
12.	Dickkamer, "C-Type Lectin-like Domains", Current Opinion in Structural Biology, Vol. 9, pg. 585-590, 1999.	
13.	Holtet, et al., "Tetranectin, a Trimeric Plasminogen-binding C-Type Lectin", Protein Science, Vol. 6, pg. 1511-1515, 1997.	
14.	Vandevoorde, et al., "Induced Expression of Trimerezed Intracellular Domains of the Human Tumor Necrosis Factor (TNF) p55 Receptor Elicits TNF Effects", The Journal of Cell Biology, Vol. 137, No. 7, pg. 1627-1638, June 30, 1997.	
15.	Chen, et al., "A Domain in TNF Receptors that Mediates Ligand-independent Receptor Assembly and Signaling", Science Vol. 288, pg. 2351-2354, June 30, 2000.	
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

INFORMATION DISCLOSURE STATEMENT BY APPUCANT		(use as many sheets as necessary)	
Application Number 10/533,290		Filing Date April 29, 2005	First Named Inventor Thor LAS HOLTE, et al
At Unit To Be Assigned		Att Examiner Name TO BE ASSIGNED	Attorney Docket Number 66611.000011
Sheet 2 of 2			

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
PTO/SB/088 (08/03) (modified)